Anavex Life Sciences Corp (AVXL)

[B60611]

1) A re-valuation that takes past catalysts into proper account. This may or may not occur in the relative near-term.

2) A run-up to ALZ results where investors determine the likelihood of success vis a vis the market size of a successful drug and all the other indications that could be treated with the MOA. Currently, the odds of a successful ALZ trial are being factored in between 3-4% or so (and < 1% when you consider MOA validation), which is ludicrously low. The run-up WILL occur in the relative near-term, the only question is how much.